



Crucell Signs PER.C6™ Agreement with NatImmune

Leiden, The Netherlands, September 5, 2002 – Dutch antibody and vaccine company Crucell N.V. (Euronext, NASDAQ: CRXL) today announced that it has signed a PER.C6™ research licensing agreement with the Danish company NatImmune A/S, to evaluate the production of the therapeutic protein, mannan-binding lectin (MBL) on PER.C6™ cells.

Under the terms of the agreement, NatImmune will evaluate the production of MBL on the PER.C6™. Additionally, NatImmune has an option for a non-exclusive commercial product license to manufacture potential MBL products. Crucell will receive upfront and annual payments, as well as royalties on net sales of marketed MBL products. Further financial details were not disclosed.

“Crucell’s PER.C6™ human cell line is fast becoming the production method of choice for a large range of biopharmaceuticals. This agreement with NatImmune further highlights the suitability of PER.C6™ as a manufacturing platform for human therapeutic proteins,” said Ronald Brus M.D., Chief Business Officer of Crucell.

MBL is a natural human protein that plays a key role in first line immune defence. It is capable of clearing a wide range of bacteria, viruses, fungi and parasites, through binding to the microorganism and activating other parts of the body’s immune system. MBL-deficiency affects 35% of the population. However, due to a large amount of overlap in the immune system, an MBL-deficiency does not manifest itself in clinical symptoms unless the individual is immunosuppressed or suffering from certain diseases.

MBL is NatImmune’s lead product candidate. MBL will initially be developed as a treatment for MBL-deficient individuals for either: 1) stabilization of disease progression in terminally ill cystic fibrosis, or 2) prevention of infections in cancer patients undergoing chemotherapy. Other conditions that seem likely indications for MBL-replacement therapy include premature babies, recurrent infections primarily in young children, spontaneous recurring miscarriages, and poor immune responses to certain types of vaccines.

About Crucell

Crucell discovers and develops biopharmaceuticals that use the human immune system to combat cancer, infectious diseases and other conditions. Crucell leverages its patented technologies, MAbstract™, AdVac™, and PER.C6™, for discovery, development and production of antibodies and vaccines. Crucell offers its technologies to the pharmaceutical and biotechnology industry and also uses them to



create its own product pipeline. Partners include Merck & Co. for the HIV vaccine, the National Institutes of Health (NIH) for the Ebola vaccine and Centocor, a Johnson & Johnson company, for the CD46 antibody for treatment of various types of cancer. In addition, Crucell has over 20 licensees for its PER.C6TM technology. These include Novartis, GSK, Aventis and Schering AG. With headquarters in Leiden, The Netherlands, the company currently employs 200 people. Crucell is listed on Euronext and NASDAQ (ticker symbol CRXL). For more information visit www.crucell.com.

For further information please contact:

Crucell N.V.

Louise Dolfing
Communications Officer
Tel. +31-(0)71-524 8863
Fax.+31-(0)71-524 8935
l.dolfing@crucell.com

Noonan Russo Presence, New York

Mary Claire Duch
Tel. +1-212-845-4278
Fax.+1-212-696-9180
m.duch@nrp-euro.com

Hill & Knowlton Nederland B.V.

Arie Bos
Tel. +31-(0)20-404 4707
Fax.+31-(0)20-644 9736
abos@hillandknowlton.com